All In MedTech

FDA Clearance Tracker · P100047-S090

HeartWare™ HVAD™ System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 27, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 27, 2017

Approved

Time to decision

239 days

Received Jan 31, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P100047-S090
Device name
HeartWare™ HVAD™ System
Applicant
Medtronic
Applicant location
Mounds View, MN
Received
Jan 31, 2017
Decided
Sep 27, 2017
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P100047

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code DSQ

FDA's approval statement

As written in FDA's record.

Approval for the HeartWare HVAD System. This device is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.

Source documents

Other decisions for Medtronic

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.